1. Home
  2. PTCT vs ICUI Comparison

PTCT vs ICUI Comparison

Compare PTCT & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTCT
  • ICUI
  • Stock Information
  • Founded
  • PTCT 1998
  • ICUI 1984
  • Country
  • PTCT United States
  • ICUI United States
  • Employees
  • PTCT N/A
  • ICUI N/A
  • Industry
  • PTCT Biotechnology: Pharmaceutical Preparations
  • ICUI Medical/Dental Instruments
  • Sector
  • PTCT Health Care
  • ICUI Health Care
  • Exchange
  • PTCT Nasdaq
  • ICUI Nasdaq
  • Market Cap
  • PTCT 3.7B
  • ICUI 3.4B
  • IPO Year
  • PTCT 2013
  • ICUI 1992
  • Fundamental
  • Price
  • PTCT $48.52
  • ICUI $134.86
  • Analyst Decision
  • PTCT Buy
  • ICUI Strong Buy
  • Analyst Count
  • PTCT 13
  • ICUI 5
  • Target Price
  • PTCT $62.31
  • ICUI $196.75
  • AVG Volume (30 Days)
  • PTCT 1.6M
  • ICUI 283.6K
  • Earning Date
  • PTCT 05-06-2025
  • ICUI 05-08-2025
  • Dividend Yield
  • PTCT N/A
  • ICUI N/A
  • EPS Growth
  • PTCT N/A
  • ICUI N/A
  • EPS
  • PTCT 7.51
  • ICUI N/A
  • Revenue
  • PTCT $1,772,758,000.00
  • ICUI $2,420,093,000.00
  • Revenue This Year
  • PTCT $99.06
  • ICUI N/A
  • Revenue Next Year
  • PTCT N/A
  • ICUI N/A
  • P/E Ratio
  • PTCT $6.46
  • ICUI N/A
  • Revenue Growth
  • PTCT 91.12
  • ICUI 7.22
  • 52 Week Low
  • PTCT $28.72
  • ICUI $101.44
  • 52 Week High
  • PTCT $58.38
  • ICUI $196.26
  • Technical
  • Relative Strength Index (RSI)
  • PTCT 55.25
  • ICUI 48.47
  • Support Level
  • PTCT $44.54
  • ICUI $127.91
  • Resistance Level
  • PTCT $49.15
  • ICUI $135.62
  • Average True Range (ATR)
  • PTCT 1.72
  • ICUI 4.35
  • MACD
  • PTCT 0.48
  • ICUI -0.26
  • Stochastic Oscillator
  • PTCT 87.67
  • ICUI 33.77

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Share on Social Networks: